Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary disease (COPD). We have evaluated its antiinflammatory effects in 59 patients with COPD randomized to receive cilomilast, 15 mg two times a day, or placebo for 12 weeks. I...

Full description

Bibliographic Details
Main Authors:	Gamble, E, Grootendorst, D, Brightling, C, Troy, S, Qiu, Y, Zhu, J, Parker, D, Matin, D, Majumdar, S, Vignola, A, Kroegel, C, Morell, F, Hansel, T, Rennard, S, Compton, C, Amit, O, Tat, T, Edelson, J, Pavord, I, Rabe, K, Barnes, N, Jeffery, P
Format:	Journal article
Language:	English
Published:	2003

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

Similar Items